Description
EMPAVRIXA-L contains Empagliflozin and Linagliptin Tablets. This combination is used to help manage blood glucose levels in adults with Type 2 Diabetes Mellitus when prescribed by a qualified healthcare professional.
Empagliflozin helps the kidneys remove excess glucose through urine. Linagliptin helps improve insulin release and reduces excess glucose production after meals. Therefore, both medicines work through different mechanisms to support blood sugar control.
Brand Name: EMPAVRIXA-L
Composition: Empagliflozin + Linagliptin Tablets
Dosage Form: Tablets
Therapeutic Category: Antidiabetic Medicine
Indication: Type 2 Diabetes Mellitus
Company: Rapid Life Drugs & Healthcare
Empagliflozin + Linagliptin Tablets
Empagliflozin + Linagliptin Tablets combine two antidiabetic medicines in one formulation. Doctors may prescribe this combination when additional blood glucose control is needed along with diet and exercise.
Empagliflozin belongs to the SGLT2 inhibitor class. It reduces the reabsorption of glucose by the kidneys. As a result, the body removes more glucose through urine.
Linagliptin belongs to the DPP-4 inhibitor class. It helps increase insulin release when blood glucose levels are elevated. It also reduces the release of hormones that increase blood glucose.
Together, these medicines provide complementary actions for blood glucose management in suitable patients.
Uses of EMPAVRIXA-L
Doctors may prescribe EMPAVRIXA-L to:
- Manage Type 2 Diabetes Mellitus
- Improve blood glucose control
- Support diabetes treatment along with diet and exercise
- Provide combination antidiabetic therapy
- Help patients who require more than one medicine for blood sugar management
This medicine is not intended as a standard treatment for Type 1 Diabetes Mellitus or diabetic ketoacidosis.
How Does EMPAVRIXA-L Work?
Empagliflozin
Empagliflozin blocks the SGLT2 protein in the kidneys. This reduces glucose reabsorption and allows more glucose to leave the body through urine.
Linagliptin
Linagliptin blocks the DPP-4 enzyme. This helps increase the activity of incretin hormones, which support insulin release when blood glucose is elevated.
Combined Action
Empagliflozin and Linagliptin work through different pathways. Therefore, their combination can provide additional blood glucose control when prescribed for appropriate patients.
Benefits of Empagliflozin + Linagliptin Tablets
EMPAVRIXA-L provides complementary actions for blood glucose management:
- Helps support better blood sugar control
- Combines Empagliflozin and Linagliptin in one formulation
- Supports Type 2 Diabetes management
- Works through two different mechanisms
- Can complement a healthy diet and regular physical activity
- Provides convenient combination therapy when prescribed
Dosage and Administration
Take EMPAVRIXA-L only as prescribed by your doctor. The appropriate dose depends on your medical condition, kidney function, blood glucose levels and response to treatment.
Take the tablet with water and follow the prescribed schedule. Do not change the dose or stop treatment without medical advice.
Your doctor may recommend regular monitoring of blood glucose and kidney function during treatment.
Possible Side Effects
Some patients may experience side effects while taking Empagliflozin and Linagliptin. These may include:
- Increased urination
- Increased thirst
- Urinary tract infection
- Genital fungal infection
- Nausea
- Headache
- Nasal congestion
- Low blood sugar when used with certain other antidiabetic medicines
Side effects can vary between patients. Contact your doctor if any side effect becomes severe or continues for a long time.
Precautions
Before starting EMPAVRIXA-L, tell your doctor about your medical history. Also, share details of all medicines and supplements you currently take.
Your doctor may need to monitor you carefully if you have:
- Kidney problems
- Liver problems
- A history of urinary or genital infections
- Dehydration or low blood pressure
- Pancreatic problems
- A history of diabetic ketoacidosis
Empagliflozin can increase glucose loss through urine. Therefore, drink adequate fluids unless your doctor has advised you to restrict fluid intake.
Seek medical attention if you develop symptoms such as severe weakness, persistent vomiting, abdominal pain or difficulty breathing.
Why Choose EMPAVRIXA-L from Rapid Life Drugs & Healthcare?
Rapid Life Drugs & Healthcare offers pharmaceutical products across different therapeutic categories. EMPAVRIXA-L – Empagliflozin + Linagliptin Tablets is part of its antidiabetic product portfolio.
The combination brings together two different mechanisms to support blood glucose management in suitable patients with Type 2 Diabetes Mellitus.
For product information, availability and pharmaceutical business enquiries, contact Rapid Life Drugs & Healthcare.
Frequently Asked Questions
What is EMPAVRIXA-L?
EMPAVRIXA-L is a combination formulation containing Empagliflozin + Linagliptin Tablets. Doctors may prescribe it to manage Type 2 Diabetes Mellitus.
What is the composition of EMPAVRIXA-L?
EMPAVRIXA-L contains Empagliflozin and Linagliptin. Please confirm the exact strengths from the approved product specification and packaging before publishing.
What is Empagliflozin + Linagliptin used for?
Doctors may use this combination to help control blood glucose levels in adults with Type 2 Diabetes Mellitus.
How does Empagliflozin work?
Empagliflozin helps the kidneys remove excess glucose through urine. This action lowers the amount of glucose in the blood.
How does Linagliptin work?
Linagliptin increases the activity of incretin hormones. These hormones help the body release insulin when blood glucose levels are elevated.
Is EMPAVRIXA-L a prescription medicine?
Yes. Use EMPAVRIXA-L only under the guidance of a qualified healthcare professional.
Can EMPAVRIXA-L be used for Type 1 Diabetes?
EMPAVRIXA-L is intended for Type 2 Diabetes Mellitus. It is not a standard treatment for Type 1 Diabetes.
About Rapid Life Drugs & Healthcare
Rapid Life Drugs & Healthcare is a pharmaceutical company offering products across different therapeutic segments. Its portfolio includes formulations for diabetes and other healthcare requirements.
The company offers EMPAVRIXA-L – Empagliflozin + Linagliptin Tablets as part of its antidiabetic product range.
For product enquiries and pharmaceutical business opportunities, contact Rapid Life Drugs & Healthcare.
